Compass Therapeutics, Inc.
corporate_fare Company Profile
Compass Therapeutics, Inc. (NASDAQ:CMPX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for CMPX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for CMPX spans 8-K, 10-Q, DEF 14A, 10-K.
Recent high-impact activity:
- Compass Therapeutics Receives Nasdaq Deficiency Letter After 30 Days Below $1.00
- Compass Q3 Loss Widens to $27.2M as Tovecimig Manufacturing Spend Jumps; $163M Cash Runs Into 2028
- Compass Q3: $163M Cash Into 2028, Loss Widens to $27.2M as FDA Standoff Persists
- FDA Demands Survival Trial Before Tovecimig BLA, Delaying Compass Approval
- Compass Q2: Tovecimig Final ORR Reaches 18%, Cash Runway Into 2028
Financial Snapshot
Short Interest & Short Volume
18.93 days to coverFINRA reported short interest of 40,787,255 shares in CMPX as of the October 30, 2026 settlement, a 2.5% decrease from the prior period — about 18.9 days to cover at its recent average daily volume. On November 20, 2026, 39.5% of CMPX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.